股东方面，截至2025年6月30日，港通医疗股东户数8154户，较上次增加196户，户均持股市值35.28万 元，户均持股数量2.76万股。 四川港通医疗设备集团股份有限公司的主营业务是医用气体装备及系统、医用洁净装备及系统的研发、 设计、制造、集成及运维服务。公司的主要产品是医用气体装备及系统、医用洁净装备及系统、医疗设 备及其他产品销售、运维服务。公司先后被评为"国家级专精特新小巨人企业""国家级高新技术企 业""四川省行业小巨人企业""中国气体行业领军企业""全国医用气体优秀工程企业""中国医用气体装备 创新基地""全国医用气体从业人员培训基地"。 最新一期业绩显示，2025年一季报，公司实现营业收入2428.67万元，同比-68.09%；净利润157.90万 元，同比-85.25%，销售毛利率36.15%。 7月7日，港通医疗今日收盘20.95元，上涨2.65%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到395.77倍，创136天以来新低，总市值20.95亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.42倍，行业中值37.44倍，港通医疗排 名第120位。 来源 ...

Core Viewpoint - MicroPulse has submitted its IPO application to the Hong Kong Stock Exchange, aiming to enhance its AI medical capabilities and expand its healthcare management ecosystem, while attracting more investors for long-term development [1] Financial Performance - MicroPulse has reported continuous losses over the past three years, with revenues of 5.12 billion, 6.28 billion, and 6.53 billion yuan for 2022, 2023, and 2024 respectively, and net losses of 4.14 billion, 1.50 billion, and 1.93 billion yuan for the same years [2] - The company's revenue is primarily derived from three segments: full-course management services (72% of revenue), medical health product sales (19.4%), and insurance brokerage services (8.6%) for 2024 [2] Business Strategy - MicroPulse has developed a clear strategy to achieve profitability, focusing on controlling operational costs, particularly in sales and distribution, and leveraging government policies and AI technology to streamline processes [3] - The company aims to create a sustainable and diversified revenue model by expanding into adjacent fields such as insurance brokerage and medical health product sales, enhancing patient engagement and lifetime value [3] Gross Margin Analysis - MicroPulse's gross margin has been below 20% for three consecutive years (17.2%, 18.9%, and 19.9% from 2022 to 2024), attributed to strategic pricing and the initial phase of its business layout [4] - The company believes that while low gross margins may impact short-term performance, they will lead to a more stable customer base and sustained revenue in the long run [4] Competitive Landscape - The digital health sector is competitive, with listed companies such as Beijing New Oxygen Technology, Alibaba Health, JD Health, and Dingdang Health, alongside numerous unlisted firms also entering the market [5] Market Potential - MicroPulse is seen to possess unique advantages and growth potential, with the IPO expected to provide additional funding to solidify its business layout and scale operations towards profitability [6]

近日，微脉向港交所递交招股书，拟于港交所主板上市，招商证券（香港）有限公司和德意志证券亚洲 有限公司为其联席保荐人。 在公司发展历程中，曾获得源码资本、MPC、千骥资本、IDG资本及百度资本等诸多投资机构，阿里巴 巴集团首席执行官兼联合创始人吴泳铭、腾讯集团联合创始人及微光创投创始人吴霄光等知名人物的青 睐。 然而，在对招股书等相关资料进行梳理之后发现，微脉光环加身背后仍存在诸多隐忧。首先，公司主营 业务增长乏力，近年持续削减费用但仍未实现经营层面的扭亏。其次，公司虽从收入上看在业内排行第 三，但市场份额仅0.71%，高度分散的竞争格局下难见显著优势。此外，公司虽不断强调AI赋能业务， 但其AI平台含金量或不足，商业模式未跑通背景下，或难支撑40亿估值。 行业龙头本质是文字游戏？收入业内第三市场份额仅0.71% 近年来，互联网医疗、数字医疗、AI医疗等身披各种耀眼光环的企业扎堆递表港交所，除了本次递表 的微脉之外，2023年至今已有包括健康之路、健康160、微医控股、轻松健康在内的多家企业向港交所 递送招股书。 梳理汇总各家企业招股书可以发现，几乎所有企业都在通过不同的统计口径来彰显自身于行业中的领先 地位。 ...

Core Viewpoint - Chengdu High-tech Investment Group Co., Ltd. received an "AAA" rating for its 2022 third phase medium-term notes, indicating strong financial stability and operational capacity [1][2]. Group 1: Company Overview - The company remains the most important entity for park construction and operation in the Chengdu High-tech Zone, maintaining a significant regional specialization advantage [2]. - Chengdu, as a national central city, has a favorable external development environment, with its economic and fiscal strength expected to continue to enhance in 2024 [2]. Group 2: Financial Performance - The company experienced substantial revenue growth in its electronic information segment due to the acquisition of a stake in Sichuan Huakun Zhenyu Intelligent Technology Co., Ltd. [2]. - Main business revenues are derived from park operations, construction, electronic information, and merchandise sales [2]. - The overall rental and sales situation of completed parks is satisfactory, but it is sensitive to the real estate market's performance [2]. Group 3: Business Risks and Challenges - The construction business is concentrated in the Chengdu High-tech Zone, with a significant reduction in new contract amounts in 2024 [2]. - The electronic information segment's sales revenue is large, but its profitability is low, contributing minimally to overall profits [2]. - The company faces substantial funding pressure due to large-scale investment in development projects [2]. Group 4: Investment Strategy - The company engages in strategic investments in major industrial projects and advantageous enterprises within the Chengdu High-tech Zone through equity direct investment and fund investment [2]. - Investment income is a crucial component of the company's profits, but investment risks must be monitored [2]. Group 5: Asset and Debt Management - The company's asset structure is balanced, with significant holdings in cash, equity, debt investments, and park-related projects [2]. - There is a rapid increase in debt levels, leading to a heavy overall debt burden, with a high proportion of short-term debt [2]. - The company has received substantial capital and asset injections from shareholders, leading to continuous growth in owner equity [2].

截至2025年一季报，共有21家机构持仓通策医疗，其中基金18家、其他3家，合计持股数20958.98万 股，持股市值94.88亿元。 通策医疗股份有限公司的主营业务是口腔医疗服务的提供、研发。公司的主要产品是医疗服务、产品销 售、建筑工程、综合服务费。 6月24日，通策医疗今日收盘40.74元，上涨1.34%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到35.58倍，总市值182.23亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均39.95倍，行业中值41.77倍，通策医疗排 名第26位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)10通策医疗35.5836.344.33182.23亿行业平均 39.9545.993.45157.13亿行业中值41.7751.452.6755.94亿1药明康德17.1720.313.081919.79亿2康龙化成 22.5823.533.00421.97亿3诺泰生物24.6829.954.41121.11亿4普蕊斯25.9022.182.0023.60亿5诺禾致源 27.5128.432.2155.94亿6诺思格30.8131.4 ...

民生证券股份有限公司 关于广州市品高软件股份有限公司 上海证券交易所： 根据贵所《关于广州市品高软件股份有限公司2024年年度报告的信息披露监 管问询函》（证科创公函【2025】0238号）（以下简称"年报问询函"）的要求， 民生证券股份有限公司（以下简称"持续督导机构"）作为广州市品高软件股份 有限公司（以下简称"品高股份"或"公司"）首次公开发行股票并在科创板上 市的保荐机构，会同公司及相关中介机构，就年报问询函提及的事项逐项进行了 认真讨论、核查与落实，出具本核查意见。 除另有说明外，本核查意见中的简称或名词的释义与《广州市品高软件股份 有限公司2024年年度报告》（以下简称"2024年报"）中的含义相同。 本核查意见中可能存在个别数据加总后与相关汇总数据存在尾差，均系数据 计算时四舍五入造成。 问题一 关于经营业绩 年报显示，公司 2024 年实现营业收入 5.20 亿元，同比减少 4.81%；实现归 母净利润-6,405.52 万元，同比减少 499.74%；实现扣非后归母净利润-7,188.47 万元，同比减少 218.09%。公司近三年实现归母净利润分别为 4,710.61 万元、 -1,068 ...

财务报表附注 上海新致软件股份有限公司 二○二四年度财务报表附注 （除特殊注明外，金额单位均为人民币元） 公司基本情况 上海新致软件股份有限公司（以下简称"公司"或"本公司"）是在原上海新致软 件有限公司基础上整体变更设立的股份有限公司，由上海前置通信技术有限公司、 上海中件管理咨询有限公司、大连软件园股份有限公司、旺道有限公司、常春藤（昆 山）产业投资中心（有限合伙）、青岛常春藤创业投资中心（有限合伙）、杭州维思 捷朗股权投资合伙企业（有限合伙）、英属维尔京群岛 Oasis Cove Investments Limited、 英属维尔京群岛 Acmecity Limited、英属维尔京群岛 Central Era Limited、TIS 株式 会社作为发起人共同发起设立的股份有限公司。公司的企业法人统一社会信用代码 为：913100006075916282。2020 年 12 月在上海证券交易所上市。所属行业为软件 和信息技术服务业类。 截至 2024 年 12 月 31 日止，本公司累计发行股本总数 26,521.7244 万股，注册地： 上海市浦东新区康杉路 308 号，总部地址：上海市浦东新区康杉路 ...

Company Overview - Beijing Zhongyan Dadi Technology Co., Ltd. specializes in geotechnical engineering and environmental remediation design and production [1] - The company is recognized as a national high-tech enterprise and has received multiple prestigious awards, including the "National Technology Invention Second Prize" and the "Hua Xia Construction Science and Technology Second Prize" [1] Financial Performance - For Q1 2025, the company reported revenue of 162 million yuan, representing a year-on-year increase of 18.50% [1] - The net profit for the same period was 10.37 million yuan, showing a significant year-on-year growth of 153.13% [1] - The sales gross margin stood at 28.20% [1] Market Position - As of June 18, the company's stock closed at 35.26 yuan, down 6.22%, with a rolling price-to-earnings (PE) ratio of 65.06 times [1] - The total market capitalization of the company is 4.469 billion yuan [1] - In comparison to the engineering consulting services industry, which has an average PE of 56.54 times and a median of 38.62 times, Zhongyan Dadi ranks 36th [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders for Zhongyan Dadi reached 9,476, an increase of 1,735 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]

序号股票简称PE(TTM)PE(静)市净率总市值(元)17兰卫医学-32.49-35.212.3438.53亿行业平均 50.8049.074.67108.36亿行业中值36.7136.842.4850.19亿1天益医疗-1758.71-3012.481.8822.41亿2澳华内 镜-655.90328.975.2569.12亿3诺唯赞-427.65-505.802.3591.52亿4爱朋医疗-397.87302.264.7932.65亿5博晖 创新-335.73532.763.5849.26亿6奥精医疗-136.87-200.611.8125.40亿7硕世生物-136.24-1990.831.2239.85亿 8睿昂基因-101.37-83.231.4413.12亿9康泰医学-88.33-74.633.1558.14亿10中红医疗-72.73-58.010.9250.55亿 11热景生物-55.61-64.074.10122.37亿 来源：金融界 6月3日，兰卫医学今日收盘9.62元，上涨2.45%，最新市净率2.34，创39天以来新低，总市值38.53亿 元。 上海兰卫医学检验所股份有限公司的主营业务是向 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)17兰卫医学-31.71-34.372.2837.61亿行业平均 49.6547.974.58106.53亿行业中值36.0336.922.4549.90亿1天益医疗-1750.39-2998.211.8722.31亿2澳华内 镜-645.17323.585.1767.99亿3诺唯赞-407.77-482.282.2487.26亿4爱朋医疗-390.19296.434.7032.02亿5博晖 创新-327.38519.513.4948.03亿6奥精医疗-139.75-204.831.8425.94亿7硕世生物-136.26-1991.121.2239.86亿 8睿昂基因-101.63-83.441.4413.15亿9康泰医学-87.30-73.763.1257.46亿10中红医疗-72.40-57.740.9250.31亿 11华大智造-55.09-48.893.79293.73亿 来源：金融界 上海兰卫医学检验所股份有限公司的主营业务是向各级医疗机构提供第三方医学检验和病理诊断服务、 国内外知名品牌体外诊断产品以及其他专业技术支持。公司的主要产品是体外诊 ...